Evidence map›Paper›PMID 40129931›Full record

ArticleFrontiers in cellular and infection microbiology2025

Distinct gut microbiome features characterize

Giljae Lee, Bruce A Rosa, Martha V Fernandez-Baca, John Martin, Rodrigo A Ore, Pedro Ortiz, Miguel M Cabada, Makedonka Mitreva

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Giljae Lee *Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Bruce A Rosa *Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Martha V Fernandez-BacaDivision of Infectious Diseases, Department of Internal Medicine, The University of Texas Medical Branch, Galveston, TX, United States.
John MartinDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Rodrigo A OreSede Cusco, Instituto de Medicina Tropical "Alexander von Humboldt", Universidad Peruana Cayetano Heredia, Cusco, Peru.
Pedro OrtizFaculty of Veterinary Science, Universidad Nacional de Cajamarca, Cajamarca, Peru.
Miguel M CabadaDivision of Infectious Diseases, Department of Internal Medicine, The University of Texas Medical Branch, Galveston, TX, United States.
Makedonka MitrevaDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
One-Health Approach to Study Human Fasciola hepatica Transmission and Inform Strategic ControlU01AI168622 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MIGUEL MAURICIO CABADA · 2022 to 2026
$2.4M
Markers of Triclabendazole Resistant Fascioliasis in the Highlands of PeruR01AI146353 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI CABADA, MIGUEL MAURICIO, MITREVA, MAKEDONKA · 2019 to 2022
$2.0M
NCI NIH HHS P30 CA091842NIAID NIH HHS R01 AI146353NIAID NIH HHS U01 AI168622
6 · The paper itself

Abstract

Background: Methods: In this study, we investigated the relationship between Results and discussion: Infection was associated with specific microbial taxonomic and functional features, including higher abundance of Conclusions: Our findings underscore the impact of helminth infection on gut microbiome and suggest a potential role of gut microbiota in modulating TCBZ efficacy, offering novel insights into

Indexed as

AnthelminticsFasciola hepaticaFascioliasisGastrointestinal MicrobiomeTriclabendazoleAdultAnimalsBacteriaFemaleHumansLongitudinal StudiesMaleMetagenomicsMiddle AgedPeruTreatment OutcomeAnthelminticsTriclabendazoleFasciola hepaticaintestinal microbiomeliver flukelongitudinal studymetagenomic shotgun sequencingtreatment responsetriclabendazole

Identifiers

PMID40129931
PMCPMC11931013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.